High LEF1 expression predicts adverse prognosis in chronic lymphocytic leukemia and may be targeted by ethacrynic acid

Aberrant activation of lymphoid enhancer-binding factor-1 (LEF1) has been identified in several cancers, including chronic lymphocytic leukemia (CLL). As a key transcription factor of the Wnt/β-catenin pathway, LEF1 helps to regulate important genes involved in tumor cell death mechanisms. In this study, we determined LEF1 gene expression levels in CLL (n = 197) and monoclonal B-cell lymphocytosis (MBL) (n = 6) patients through real-time RT-PCR. LEF1 was significantly up-regulated in both MBL and CLL patients compared with normal B cells. Treatment-free survival (TFS) time and overall survival (OS) time were much longer in CLL patients with low LEF1 expression than in those with high LEF1 levels. Furthermore, Wnt inhibitor ethacrynic acid (EA) induced both apoptosis and necroptosis in primary CLL cells. EA also enhanced the cytotoxicity of both fludarabine and cyclophosphamide against CLL cells in vitro. Finally, we demonstrated that EA functions by inhibiting the recruitment of LEF1 to DNA promoters and restoring cylindromatosis (CYLD) expression in CLL cells. Our results showed, for the first time, that high LEF1 expression is associated with poor survival for CLL patients. Combined with other chemotherapeutic drugs, EA may be a promising therapeutic agent for CLL.

• Publication year

  2016

• Venue

  OncoTarget

• Publication date

  2016-02-29

• Fields of study

  Medicine

• Identifiers
  DOI 10.18632/oncotarget.7795PMID 26950276PMCID 5008311
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cellular proteolytic modification of tumor-suppressor CYLD is critical for the initiation of human T-cell acute lymphoblastic leukemia.

  2015cited by this paper
• Clinical significance of down-regulated cylindromatosis gene in chronic lymphocytic leukemia

  2014cited by this paper
• The legal status of in vitro embryos

  2014cited by this paper
• Inhibition of GSK3B Bypass Drug Resistance of p53-Null Colon Carcinomas by Enabling Necroptosis in Response to Chemotherapy

  2013cited by this paper
• Lymphoid enhancer binding factor-1 (LEF1) expression as a prognostic factor in adult acute promyelocytic leukemia

  2013cited by this paper
• Wnt Signaling in Stem Cells and Cancer

  2013cited by this paper
• Genome-wide Association Study Identifies Multiple Risk Loci for Chronic Lymphocytic Leukemia

  2013cited by this paper
• Ethacrynic Acid and a Derivative Enhance Apoptosis in Arsenic Trioxide–Treated Myeloid Leukemia and Lymphoma Cells: The Role of Glutathione S-Transferase P1-1

  2012cited by this paper
• Necroptosis: an emerging form of programmed cell death.

  2012cited by this paper
• High expression of lymphoid enhancer-binding factor-1 (LEF1) is a novel favorable prognostic factor in cytogenetically normal acute myeloid leukemia.

  2012cited by this paper
• Overexpression of LEF1 predicts unfavorable outcome in adult patients with B-precursor acute lymphoblastic leukemia.

  2011cited by this paper
• Increased in vivo efficacy of lenalidomide and thalidomide by addition of ethacrynic acid.

  2011cited by this paper
• The Notch/Hes1 pathway sustains NF-κB activation through CYLD repression in T cell leukemia.

  2010cited by this paper
• CYLD: a tumor suppressor deubiquitinase regulating NF-κB activation and diverse biological processes

  2010cited by this paper
• High lymphoid enhancer-binding factor-1 expression is associated with disease progression and poor prognosis in chronic lymphocytic leukemia

  2010cited by this paper
• Dysregulation of TNFα-induced necroptotic signaling in chronic lymphocytic leukemia: suppression of CYLD gene by LEF1

  2010cited by this paper
• LEF-1 is a prosurvival factor in chronic lymphocytic leukemia and is expressed in the preleukemic state of monoclonal B-cell lymphocytosis.

  2010cited by this paper
• Small molecule inhibitors of Wnt/beta-catenin/lef-1 signaling induces apoptosis in chronic lymphocytic leukemia cells in vitro and in vivo.

  2010cited by this paper
• Small Molecule Inhibitors of Wnt/β-Catenin/Lef-1 Signaling Induces Apoptosis in Chronic Lymphocytic Leukemia Cells In Vitro and In Vivo

  2010cited by this paper
• Small Molecule Inhibitors of Wnt/β-Catenin/Lef-1 Signaling Induces Apoptosis in Chronic Lymphocytic Leukemia Cells

  2010cited by this paper
• Ethacrynic Acid Exhibits Selective Toxicity to Chronic Lymphocytic Leukemia Cells by Inhibition of the Wnt/β-Catenin Pathway

  2009cited by this paper
• Necrostatin-1 reverts shikonin-induced necroptosis to apoptosis

  2009cited by this paper
• Acute Myeloid Leukemia-Targeted Toxin Activates Both Apoptotic and Necroptotic Death Mechanisms

  2008cited by this paper
• Identification of a molecular signaling network that regulates a cellular necrotic cell death pathway.

  2008cited by this paper
• A novel role for Lef-1, a central transcription mediator of Wnt signaling, in leukemogenesis

  2008cited by this paper
• Bypassing cancer drug resistance by activating multiple death pathways--a proposal from the study of circumventing cancer drug resistance by induction of necroptosis.

  2008cited by this paper
• Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma.

  2007cited by this paper
• Notch1 co-opts lymphoid enhancer factor 1 for survival of murine T-cell lymphomas.

  2007cited by this paper
• Variation of LEF-1 mRNA expression in low-grade B-cell non-Hodgkin's lymphoma.

  2006cited by this paper
• Wnt signaling in stem cells and cancer

  2006cited by this paper
• Wnt signalling in stem cells and cancer

  2005cited by this paper
• In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells.

  2005cited by this paper
• Expression of ZAP-70 Protein Correlates with Disease Stage in Chronic Lymphocytic Leukemia and is Associated with, but not Generally Restricted to, Non-mutated Ig VH Status

  2004cited by this paper
• The tumour suppressor CYLD negatively regulates NF-κB signalling by deubiquitination

  2003cited by this paper
• ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia.

  2003cited by this paper
• Characterization of cell death induced by ethacrynic acid in a human colon cancer cell line DLD‐1 and suppression by N‐acetyl‐l‐cysteine

  2003cited by this paper
• Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors.

  2002cited by this paper
• Wnt signaling regulates B lymphocyte proliferation through a LEF-1 dependent mechanism.

  2000cited by this paper
• Redundant regulation of T cell differentiation and TCRalpha gene expression by the transcription factors LEF-1 and TCF-1.

  1998cited by this paper
• Inhibitors of glutathione S-transferases as therapeutic agents.

  1997cited by this paper
• Pharmakokinetics and bioavailability study of ethacrynic acid as a modulator of drug resistance in patients with cancer.

  1994cited by this paper
• Reversing of chlorambucil resistance by ethacrynic acid in a B‐CLL patient

  1993cited by this paper
• Resistance circumvention strategies tested in clinical leukaemia specimens using the MTT colorimetric assay.

  1992cited by this paper
• Selective toxicity of ethacrynic acid towards lymphocytes of chronic lymphocytic leukemia in vitro.

  1992cited by this paper
• Phase I study of thiotepa in combination with the glutathione transferase inhibitor ethacrynic acid.

  1991cited by this paper

• Metastatic melanoma: An integrated analysis to identify critical regulators associated with prognosis, pathogenesis and targeted therapies

  2025cites this paper
• PKCβ inhibitor MS-553 displays preclinical efficacy in both treatment-naïve and BTK inhibitor-resistant Chronic Lymphocytic Leukemia.

  2025cites this paper
• Discovery of repurposed ethacrynic acid and its derivatives as novel TEAD inhibitors.

  2025cites this paper
• The Role of LEF1 Protein in Chronic Lymphocytic Leukemia and Different Treatment Methods

  2025influential citation
• Tumor microenvironment as a novel therapeutic target for lymphoid leukemias

  2025cites this paper
• The influence of lymphoid enhancer binding factor-1 expression on the outcome of adult acute promyelocytic leukemia patients

  2025cites this paper
• Immunohistochemical Investigation into Protein Expression Patterns of FOXO4, IRF8 and LEF1 in Canine Osteosarcoma

  2024cites this paper
• Alterations in miRNA Expression and Their Role in the Pathogenesis of Cervical Cancer

  2024cites this paper
• Deregulation of New Cell Death Mechanisms in Leukemia

  2024cites this paper
• Effect of Aza-BODIPY-Photodynamic Therapy on The Expression of Carcinoma-Associated Genes and Cell Death Mode.

  2023cites this paper
• Ethacrynic Acid: A Promising Candidate for Drug Repurposing as an Anticancer Agent

  2023cites this paper
• Identification of splicing defects caused by novel exonic mutations in LEF1 in Sudanese B- chronic lymphocytic leukemia patients: computational approach

  2022cites this paper
• To β or Not to β: How Important Is β-Catenin Dependent and Independent WNT Signaling in CLL?

  2022cites this paper
• PKCβ Facilitates Leukemogenesis in Chronic Lymphocytic Leukaemia by Promoting Constitutive BCR-Mediated Signalling

  2022cites this paper
• Necroptosis-Related Prognostic Signature and Nomogram Model for Predicting the Overall Survival of Patients with Lung Cancer

  2022cites this paper
• The Prognostic and Drug-Targeting Value of Lymphoid Enhancer-Binding Factor-1 in Hepatocellular Carcinoma.

  2022cites this paper
• High miR-34a and miR-26b expressions inhibit prostate cancer cell OPCN-1 proliferation and enhances apoptosis

  2022cites this paper
• Differential Levels of mRNAs in Normal B Lymphocytes, Monoclonal B Lymphocytosis and Chronic Lymphocytic Leukemia Cells from the Same Family Identify Susceptibility Genes

  2021cites this paper
• Prognostic evidence of LEF1 isoforms in childhood acute lymphoblastic leukemia

  2021cites this paper
• Downregulation of LEF1 Impairs Myeloma Cell Growth Through Modulating CYLD/NF-κB Signaling

  2021cites this paper
• Wnt/β-catenin signaling in cancers and targeted therapies

  2021cites this paper
• Deubiquitinases in hematological malignancies

  2021cites this paper
• Wnt pathway modulators in cancer therapeutics: An update on completed and ongoing clinical trials

  2021cites this paper
• LncRNA landscape analysis identified LncRNA LEF-AS1 as an oncogene that upregulates LEF1 and promotes survival in chronic lymphocytic leukemia.

  2021cites this paper
• CYLD in Hematological Malignancies

  2021cites this paper
• MiR-34a-5p Inhibits Proliferation, Migration, Invasion and Epithelial-mesenchymal Transition in Esophageal Squamous Cell Carcinoma by Targeting LEF1 and Inactivation of the Hippo-YAP1/TAZ Signaling Pathway

  2020cites this paper
• WNT3 and LEF1 as markers for diagnosis and survival prediction in chronic lymphocytic leukemia patients

  2020cites this paper
• Cinobufagin Suppresses Melanoma Cell Growth by Inhibiting LEF1

  2020cites this paper
• LEF 1 induces DHRS 2 gene expression in human acute leukemia

  2020cites this paper
• LEF1 Induces DHRS2 Gene Expression in Human Acute Leukemia Jurkat T-Cells

  2020cites this paper
• Recent Development of Wnt Signaling Pathway Inhibitors for Cancer Therapeutics

  2019cites this paper
• Dissecting the role of lymphoid enhancer factor 1 (LEF1) in acute myeloid leukemia

  2019cites this paper
• Expression of LEF1 and TCF1 (TCF7) proteins associates with clinical progression of nasopharyngeal carcinoma

  2019cites this paper
• Role of long non-coding RNAs in disease progression of early stage unmutated chronic lymphocytic leukemia

  2019cites this paper
• Lymphoid enhancer-binding factor-1 promotes stemness and poor differentiation of hepatocellular carcinoma by directly activating the NOTCH pathway

  2019cites this paper
• Targeting the Versatile Wnt/β-Catenin Pathway in Cancer Biology and Therapeutics: From Concept to Actionable Strategy

  2019cites this paper
• Hsa-miR-106b-5p Negatively Regulates LEF1

  2018cites this paper
• Role of miR-452-5p in the tumorigenesis of prostate cancer: A study based on the Cancer Genome Atl(TCGA), Gene Expression Omnibus (GEO), and bioinformatics analysis.

  2018cites this paper
• Ethacrynic Acid and Ciclopiroxolamine in Various Cancer Cells

  2018cites this paper
• The Role of Expression of Lymphoid Enhancer-Binding Factor-1 (LEF-1) in Patients with Chronic Lymphocytic Leukemia

  2018cites this paper
• Morphology and Immunophenotype of Chronic Lymphocytic Leukemia

  2018cites this paper
• Alterations in WNT Signaling in Leukemias

  2018cites this paper
• Bypassing drug resistance by triggering necroptosis: recent advances in mechanisms and its therapeutic exploitation in leukemia

  2018cites this paper
• TLE1 as an indicator of adverse prognosis in pediatric acute lymphoblastic leukemia.

  2018cites this paper
• The reference epigenome and regulatory chromatin landscape of chronic lymphocytic leukemia

  2018cites this paper
• Increased SHISA3 expression characterizes chronic lymphocytic leukemia patients sensitive to lenalidomide

  2018cites this paper
• Wnt signalling pathways in chronic lymphocytic leukaemia and B‐cell lymphomas

  2017cites this paper
• Expression of LEF1 in mantle cell lymphoma.

  2017cites this paper
• Wnt signaling pathway protein LEF1 in cancer, as a biomarker for prognosis and a target for treatment.

  2017influential citation
• DNA methylation profiling reveals common signatures of tumorigenesis and defines epigenetic prognostic subtypes of canine Diffuse Large B-cell Lymphoma

  2017cites this paper